Psychedelic Spotlight News

  • Numinus Acquires Novamind: What Does This Mean for the Psychedelic Industry? | NUMI, NM

    Listen, Videos

    Numinus Acquiring Novamind in First Major Psychedelics Merger

    Get your 20%-off tickets to the Catalyst Psychedelics Summit in Kingston Ontario, May 20th-23rd: www.eventbrite.ca/e/153409882087/?discount=SPOTLIGHT20

    Not only will this be your chance to meet me, but also the legendary Paul Stamets!

    Join our Newsletter (scroll to the bottom of the page and sign up): https://psychedelicspotlight.com/psyc…

    Follow us on Twitter:
    James: @Psy_Invest
    Maria: @psy_holy
    The Psychedelic Investor: @PsycInvestor
    Psychedelic Spotlight: @PsycSpotlight

    Follow us on Instagram:
    @thepsychedelicinvestor
    @psycspotlight

    To learn more about the emerging psychedelic industry, visit:
    https://psychedelicspotlight.com/

    Back to Numinus

    This acquisition will make Numinus the psychedelic medicines company with the highest revenue, though of course there is still a long road to profitability.

    Psychedelic stock investors woke up to some major news today: Numinus Wellness (TSX: NUMI) (OTCQX: NUMIF) announced that they are acquiring Novamind Inc. (CSE: NM) (OTCQB: NVMDF).

    The acquisition will be done in stock, and shareholders of Novamind will receive 0.84 of a common share of Numinus per Novamind share held, implying an offer price of $0.44 per Novamind share. This means Numinus is offering a premium of 51% to Novamind shareholders, based on the 20-day volume-weighted average price of their stock. When the transaction is completed, Novamind shareholders will own around 18% of Numinus.

    If you currently hold Novamind stock, you do not need to do anything. When the transaction is finalized, each Novamind share you own will automatically be transformed into 0.84 of a Numinus share.

    #Numinus #NovaMind #psychedelicStocks